Literature DB >> 17285574

Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event.

Anna L Paterson1, Jessica C M Pole, Katherine A Blood, Maria J Garcia, Susanna L Cooke, Andrew E Teschendorff, Yanzhong Wang, Suet-Feung Chin, Bauke Ylstra, Carlos Caldas, Paul A W Edwards.   

Abstract

Epithelial cancers frequently have multiple amplifications, and particular amplicons tend to occur together. These co-amplifications have been suggested to result from amplification of pre-existing junctions between two chromosomes, that is, translocation junctions. We investigated this hypothesis for two amplifications frequent in breast cancer, at 8p12 and 11q13, which had been reported to be associated in Southern blot studies. We confirmed that both genomic amplification and expression of genes was correlated between the frequently-amplified regions of 8p and 11q, in array CGH and microarray expression data, supporting the importance of co-amplification. We examined by FISH the physical structure of co-amplifications that we had identified by array CGH, in five breast cancer cell lines (HCC1500, MDA-MB-134, MDA-MB-175, SUM44, and ZR-75-1), four breast tumors, and a pancreatic cancer cell line (SUIT2). We found a variety of arrangements: amplification of translocation junctions; entirely independent amplification of the two regions on separate chromosomes; and separate amplification of 8p and 11q sequences in distinct sites on the same rearranged chromosome. In this last arrangement, interphase nuclei often showed intermingling of FISH signals from 8p12 and 11q13, giving a false impression that the sequences were interdigitated. We conclude that co-amplification of the main 8p and 11q amplicons in breast tumors is not usually the result of a preceding translocation event but most likely reflects selection of clones that have amplified both loci. This article contains supplementary material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17285574     DOI: 10.1002/gcc.20424

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  Battling cancer on many fronts. Meeting on New Battlefields in Human Cancer--Attacking in Many Fronts.

Authors:  Fabian Zanella; Amancio Carnero
Journal:  EMBO Rep       Date:  2008-09       Impact factor: 8.807

2.  Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Authors:  Hege G Russnes; Hans Kristian Moen Vollan; Ole Christian Lingjærde; Alexander Krasnitz; Pär Lundin; Bjørn Naume; Therese Sørlie; Elin Borgen; Inga H Rye; Anita Langerød; Suet-Feung Chin; Andrew E Teschendorff; Philip J Stephens; Susanne Månér; Ellen Schlichting; Lars O Baumbusch; Rolf Kåresen; Michael P Stratton; Michael Wigler; Carlos Caldas; Anders Zetterberg; James Hicks; Anne-Lise Børresen-Dale
Journal:  Sci Transl Med       Date:  2010-06-30       Impact factor: 17.956

3.  Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer.

Authors:  Zhe-Wei Qiu; Jia-Hao Bi; Adi F Gazdar; Kai Song
Journal:  Genes Chromosomes Cancer       Date:  2017-05-04       Impact factor: 5.006

4.  Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression.

Authors:  Andrzej B Popławski; Michał Jankowski; Stephen W Erickson; Teresita Díaz de Ståhl; E Christopher Partridge; Chiquito Crasto; Jingyu Guo; John Gibson; Uwe Menzel; Carl Eg Bruder; Aneta Kaczmarczyk; Magdalena Benetkiewicz; Robin Andersson; Johanna Sandgren; Barbara Zegarska; Dariusz Bała; Ewa Srutek; David B Allison; Arkadiusz Piotrowski; Wojciech Zegarski; Jan P Dumanski
Journal:  Eur J Hum Genet       Date:  2010-01-06       Impact factor: 4.246

Review 5.  High throughput molecular diagnostics in bladder cancer - on the brink of clinical utility.

Authors:  Karsten Zieger
Journal:  Mol Oncol       Date:  2007-12-08       Impact factor: 6.603

6.  Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Authors:  Gabriel N Hortobagyi; David Chen; Martine Piccart; Hope S Rugo; Howard A Burris; Kathleen I Pritchard; Mario Campone; Shinzaburo Noguchi; Alejandra T Perez; Ines Deleu; Mikhail Shtivelband; Norikazu Masuda; Shaker Dakhil; Ian Anderson; Douglas M Robinson; Wei He; Abhishek Garg; E Robert McDonald; Hans Bitter; Alan Huang; Tetiana Taran; Thomas Bachelot; Fabienne Lebrun; David Lebwohl; José Baselga
Journal:  J Clin Oncol       Date:  2015-10-26       Impact factor: 44.544

7.  Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis.

Authors:  S S Kwek; R Roy; H Zhou; J Climent; J A Martinez-Climent; J Fridlyand; D G Albertson
Journal:  Oncogene       Date:  2009-03-30       Impact factor: 9.867

8.  Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes.

Authors:  Ina Schulte; Elizabeth M Batty; Jessica C M Pole; Katherine A Blood; Steven Mo; Susanna L Cooke; Charlotte Ng; Kevin L Howe; Suet-Feung Chin; James D Brenton; Carlos Caldas; Karen D Howarth; Paul A W Edwards
Journal:  BMC Genomics       Date:  2012-12-22       Impact factor: 3.969

9.  High-resolution array CGH clarifies events occurring on 8p in carcinogenesis.

Authors:  Susanna L Cooke; Jessica C M Pole; Suet-Feung Chin; Ian O Ellis; Carlos Caldas; Paul A W Edwards
Journal:  BMC Cancer       Date:  2008-10-07       Impact factor: 4.430

10.  Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11-p12-amplified breast carcinomas.

Authors:  T Z Parris; A Kovács; S Hajizadeh; S Nemes; M Semaan; M Levin; P Karlsson; K Helou
Journal:  Oncogenesis       Date:  2014-03-24       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.